Printer Friendly

CELL GENESYS ANNOUNCES KEY PRODUCT DEVELOPMENT HIRES

 FOSTER CITY, Calif., April 22 /PRNewswire/ -- Cell Genesys Inc. (NASDAQ: CEGE) announced today three key management hires with expertise in product development who joined the company during the first quarter of 1993.
 Bridget Binko, 41, has joined Cell Genesys as director of regulatory affairs, bringing nearly 10 years of pharmaceutical industry experience to her position. For the past four years, Binko was with IDEC Pharmaceuticals Corp., based in Mountain View, Calif., most recently as senior director of regulatory affairs and quality assurance. Previously, she held regulatory affairs positions with Syntex Inc., Palo Alto, Calif. Binko holds a master's degree in microbiology from the State University of New York at Buffalo and a bachelor's degree in biology from Mary Washington College, Fredericksburg, Va.
 David Broad, Ph.D., 39, has joined Cell Genesys as director of cell culture development with responsibility for manufacturing process development in the cell production area. For the past six years, Broad served in product development and manufacturing positions at Celltech Ltd., a biotechnology company locati?n England. Most recently, he was production manager with responsibility for contract manufacturing of various biological products. Previously, Broad was a senior development scientist at Beecham Pharmaceuticals in England. He received his bachelor of science and doctorate degrees in microbiology from the University of London.
 William Mueller, 35, has joined Cell Genesys as director of process recovery with responsibility for manufacturing process development in the purification area. For the past five years, Mueller was with Amgen Inc., Thousand Oaks, Calif., where he held various manufacturing and process development positions, most recently manager of clinical manufacturing. He previously held positions in process development at Universal Oil Products, a division of Allied Signal Co. Mueller holds a bachelor of science degree in chemical engineering from the University of Illinois.
 "The addition of Bridget Binko, David Broad and William Mueller to our management team brings additional expertise to Cell Genesys in important areas of product development, including regulatory affairs and manufacturing process development," said Stephen A. Sherwin, M.D., president and chief executive officer. "These new additions to our staff further enhance our ability to move our products forward in development."
 Cell Genesys is a leader in the application of gene targeting technology to the development of human therapeutic products. Gene targeting is a new cellular genetic engineering technology which enables precise and permanent activation, inactivation and replacement of specific genes in living cells. The company is applying gene targeting and related technologies to develop products in three areas: universal cell transplant products, therapeutic protein products and human monoclonal antibody products. Cell Genesys completed its initial public offering in February 1993.
 -0- 4/22/93
 /CONTACT: Stephen A. Sherwin, M.D., president and chief executive officer of Cell Genesys, 415-358-9600 ext. 212/
 (CEGE)


CO: Cell Genesys Inc. ST: California IN: MTC SU: PER

TM-TB -- SF005 -- 9544 04/22/93 14:03 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 22, 1993
Words:477
Previous Article:THE IMMUNE RESPONSE CORPORATION REPORTS FIRST QUARTER 1993 FINANCIAL RESULTS
Next Article:BROCK PARTNERS WITH STRATUS
Topics:


Related Articles
SARALYNN MANDEL JOINS CELL GENESYS AS DIRECTOR OF INTELLECTUAL PROPERTY
CELL GENESYS SCIENTISTS DEVELOP METHOD FOR INTRODUCING LARGE HUMAN GENES INTO MICE
CELL GENESYS PROMOTES KRISZTINA ZSEBO, PH.D., TO VICE PRESIDENT OF PRODUCT DEVELOPMENT
CELL GENESYS ADDS TWO KEY PRODUCT DEVELOPMENT DIRECTORS
CELL GENESYS AND JT IMMUNOTECH EXTEND RESEARCH COLLABORATION FOR HUMAN MONOCLONAL ANTIBODIES
CELL GENESYS NAMES EXECUTIVE TEAM FOR NEW SUBSIDIARY, ABGENIX
CELL GENESYS ANNOUNCES EXECUTIVE PROMOTIONS
Genzyme Molecular Oncology to Secure Cash and Cancer Programs To Advance its Cancer Product Pipeline.
Genzyme General Terminates Agreement to Acquire Cell Genesys.
Cell Genesys Licenses Lentiviral Gene Delivery Technology to Invitrogen For the Research Market.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters